Herein we describe a mutant of the two-exon HIV-1 Tat protein, termed Nullbasic, that potently inhibits multiple steps of the HIV-1 replication cycle. Nullbasic was created by replacing the entire arginine-rich basic domain of wild type Tat with glycine/alanine residues. Like similarly mutated one-exon Tat mutants, Nullbasic exhibited transdominant negative effects on Tat-dependent transactivation. However, unlike previously reported mutants, we discovered that Nullbasic also strongly suppressed the expression of unspliced and singly-spliced viral mRNA, an activity likely caused by redistribution and thus functional inhibition of HIV-1 Rev. Furthermore, HIV-1 virion particles produced by cells expressing Nullbasic had severely reduced infec...
A BK virus (BKV) expression vector, specific for human cells, was engineered to express antisense hu...
AbstractThe Tat protein of human immunodeficiency virus type 1 (HIV-1) has been shown to restrict pr...
grantor: University of TorontoThe etiologic agent of acquired immunodeficiency syndrome, ...
Herein we describe a mutant of the two-exon HIV-1 Tat protein, termed Nullbasic, that potently inhib...
Background: Nullbasic is a mutant HIV-1 Tat protein that inhibits HIV-1 replication via three indepe...
Here we show potent inhibition of HIV-1 replication in a human T cell line and primary human CD4+ ce...
HIV-1 infection is effectively controlled by antiviral therapy that inhibits virus replication and r...
Free to read\ud \ud Previously, we reported that a mutant of Tat referred to as Nullbasic inhibits H...
ABSTRACT Nullbasic is a derivative of the HIV-1 transactivator of transcription (Tat) protein that s...
Tat mutants (tat22, tat37 and tat22/37) were constructed in the transactivation domain, where cystei...
Background: Previously we described a transdominant negative mutant of the HIV-1 Tat protein, termed...
Nullbasic is a mutant form of HIV-1 Tat that has strong ability to protect cells from HIV-1 replicat...
It was previously shown that a tat mutant (tat22) where cystein 22 is substituted by glycine behaves...
It was previously shown that a tat mutant (tat22) where cysteine 22 is substituted by glycine behave...
AbstractTat is an essential regulatory protein for the replication of human immunodeficiency virus (...
A BK virus (BKV) expression vector, specific for human cells, was engineered to express antisense hu...
AbstractThe Tat protein of human immunodeficiency virus type 1 (HIV-1) has been shown to restrict pr...
grantor: University of TorontoThe etiologic agent of acquired immunodeficiency syndrome, ...
Herein we describe a mutant of the two-exon HIV-1 Tat protein, termed Nullbasic, that potently inhib...
Background: Nullbasic is a mutant HIV-1 Tat protein that inhibits HIV-1 replication via three indepe...
Here we show potent inhibition of HIV-1 replication in a human T cell line and primary human CD4+ ce...
HIV-1 infection is effectively controlled by antiviral therapy that inhibits virus replication and r...
Free to read\ud \ud Previously, we reported that a mutant of Tat referred to as Nullbasic inhibits H...
ABSTRACT Nullbasic is a derivative of the HIV-1 transactivator of transcription (Tat) protein that s...
Tat mutants (tat22, tat37 and tat22/37) were constructed in the transactivation domain, where cystei...
Background: Previously we described a transdominant negative mutant of the HIV-1 Tat protein, termed...
Nullbasic is a mutant form of HIV-1 Tat that has strong ability to protect cells from HIV-1 replicat...
It was previously shown that a tat mutant (tat22) where cystein 22 is substituted by glycine behaves...
It was previously shown that a tat mutant (tat22) where cysteine 22 is substituted by glycine behave...
AbstractTat is an essential regulatory protein for the replication of human immunodeficiency virus (...
A BK virus (BKV) expression vector, specific for human cells, was engineered to express antisense hu...
AbstractThe Tat protein of human immunodeficiency virus type 1 (HIV-1) has been shown to restrict pr...
grantor: University of TorontoThe etiologic agent of acquired immunodeficiency syndrome, ...